Ingevity (NGVT) Aktienübersicht
Die Ingevity Corporation produziert und vertreibt Aktivkohleprodukte, derivative Spezialchemikalien und technische Polymere in Nordamerika, im asiatisch-pazifischen Raum, in Europa, im Nahen Osten, in Afrika und in Südamerika. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 3/6 |
| Dividenden | 0/6 |
NGVT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ingevity Corporation Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$73.41 |
| 52-Wochen-Hoch | US$79.29 |
| 52-Wochen-Tief | US$39.74 |
| Beta | 1.19 |
| 1 Monat Veränderung | 12.57% |
| 3 Monate Veränderung | 15.39% |
| 1 Jahr Veränderung | 77.71% |
| 3 Jahre Veränderung | 41.39% |
| 5 Jahre Veränderung | -10.33% |
| Veränderung seit IPO | 173.31% |
Aktuelle Nachrichten und Updates
Analyseartikel • Jun 18
Ingevity (NGVT) Stock Could Be 14% Undervalued on Its Portfolio Reshaping Narrative
Ingevity (NGVT) stock has been in focus after recent trading performance, prompting investors to reassess how the company’s materials and specialty chemicals portfolio lines up with its current valuation and recent share price moves. See our latest analysis for Ingevity. At a share price of $73.41, Ingevity has seen a 12.90% 1 month share price return and a 22.17% year to date share price return, while its 1 year total shareholder return of 77.40% points to momentum that has been building...
Narrativ-Update • Jun 13
NGVT: Portfolio Reshaping And Buybacks Will Support Future P/E Re Rating
Analysts have maintained their $85.50 price target for Ingevity, citing largely stable assumptions around the discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their current view. What's in the News Ingevity completed the sale of its Ozark Materials Road Markings product line and divested its North Charleston CTO refinery and most of the Industrial Specialties product line, as part of a portfolio reshaping effort.Narrativ-Update • May 29
NGVT: Share Repurchases And Margin Strength Will Support Future P/E Re Rating
Analysts have maintained their $85.50 price target on Ingevity, citing consistent assumptions for revenue growth, profit margins, discount rate, and future P/E as the basis for their view. What's in the News From January 1, 2026 to March 31, 2026, Ingevity repurchased 774,189 shares, representing 2.18% of its stock, for a total of $51.94 million under its ongoing buyback program announced on August 2, 2022 (Key Developments).Seeking Alpha • May 19
Ingevity - Shrinking To Grow
Summary Ingevity is pursuing a shrink-to-grow strategy, divesting non-core assets to boost focus and margins. Recent asset sales fetched modest prices, following significant impairment charges, but have not materially impacted earnings. Ingevity´s leverage is gradually declining, with 2026 guidance targeting $4.70–$5.20 EPS and $370–$395 million adjusted EBITDA. I remain cautiously optimistic, seeing potential for re-rating if further simplification or a performance materials spin-off occurs. Read the full article on Seeking AlphaRecent updates
Analyseartikel • Jun 18
Ingevity (NGVT) Stock Could Be 14% Undervalued on Its Portfolio Reshaping Narrative
Ingevity (NGVT) stock has been in focus after recent trading performance, prompting investors to reassess how the company’s materials and specialty chemicals portfolio lines up with its current valuation and recent share price moves. See our latest analysis for Ingevity. At a share price of $73.41, Ingevity has seen a 12.90% 1 month share price return and a 22.17% year to date share price return, while its 1 year total shareholder return of 77.40% points to momentum that has been building...Narrativ-Update • Jun 13
NGVT: Portfolio Reshaping And Buybacks Will Support Future P/E Re Rating
Analysts have maintained their $85.50 price target for Ingevity, citing largely stable assumptions around the discount rate, revenue growth, profit margin, and future P/E as the basis for keeping their current view. What's in the News Ingevity completed the sale of its Ozark Materials Road Markings product line and divested its North Charleston CTO refinery and most of the Industrial Specialties product line, as part of a portfolio reshaping effort.Narrativ-Update • May 29
NGVT: Share Repurchases And Margin Strength Will Support Future P/E Re Rating
Analysts have maintained their $85.50 price target on Ingevity, citing consistent assumptions for revenue growth, profit margins, discount rate, and future P/E as the basis for their view. What's in the News From January 1, 2026 to March 31, 2026, Ingevity repurchased 774,189 shares, representing 2.18% of its stock, for a total of $51.94 million under its ongoing buyback program announced on August 2, 2022 (Key Developments).Seeking Alpha • May 19
Ingevity - Shrinking To Grow
Summary Ingevity is pursuing a shrink-to-grow strategy, divesting non-core assets to boost focus and margins. Recent asset sales fetched modest prices, following significant impairment charges, but have not materially impacted earnings. Ingevity´s leverage is gradually declining, with 2026 guidance targeting $4.70–$5.20 EPS and $370–$395 million adjusted EBITDA. I remain cautiously optimistic, seeing potential for re-rating if further simplification or a performance materials spin-off occurs. Read the full article on Seeking AlphaNarrativ-Update • May 14
NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge
Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).Narrativ-Update • Apr 28
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.Narrativ-Update • Apr 11
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.Narrativ-Update • Mar 28
NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.Narrativ-Update • Mar 13
NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.Narrativ-Update • Feb 24
NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.Narrativ-Update • Feb 09
NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook
Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.Narrativ-Update • Jan 26
NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook
Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.Narrativ-Update • Jan 10
NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook
Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.Narrativ-Update • Dec 25
NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset
Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.Narrativ-Update • Dec 10
NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential
Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.Analyseartikel • Sep 30
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...Analyseartikel • Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Narrativ-Update • Sep 05
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.Narrativ-Update • Aug 06
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.Analyseartikel • Jun 27
Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...Analyseartikel • May 28
Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...Neues Narrativ • May 27
Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Analyseartikel • Apr 05
Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...Analyseartikel • Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analyseartikel • Jan 16
Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...Analyseartikel • Nov 07
What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...Analyseartikel • Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Sep 08
Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...Seeking Alpha • Aug 27
Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking AlphaAnalyseartikel • Aug 03
Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...Analyseartikel • Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Jun 14
Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...Analyseartikel • Apr 18
Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?
Key Insights Ingevity's estimated fair value is US$78.59 based on 2 Stage Free Cash Flow to Equity Current share price...Analyseartikel • Mar 22
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aktionärsrenditen
| NGVT | US Chemicals | US Markt | |
|---|---|---|---|
| 7D | 2.0% | -1.4% | 1.4% |
| 1Y | 77.7% | 8.8% | 25.7% |
Rendite im Vergleich zur Industrie: NGVT übertraf die Branche US Chemicals , die im vergangenen Jahr eine Rendite von 8.8 erzielte.
Rendite vs. Markt: NGVT übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.7 erzielte.
Preisvolatilität
| NGVT volatility | |
|---|---|
| NGVT Average Weekly Movement | 5.0% |
| Chemicals Industry Average Movement | 6.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: NGVT hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: NGVTDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1964 | 1,500 | Dave Li | www.ingevity.com |
Die Ingevity Corporation produziert und vertreibt Aktivkohleprodukte, derivative Spezialchemikalien und technische Polymere in Nordamerika, im asiatisch-pazifischen Raum, in Europa, im Nahen Osten, in Afrika und in Südamerika. Das Unternehmen ist in drei Segmenten tätig: Performance Materials, Performance Chemicals und Advanced Polymer Technologies. Das Segment Performance Materials entwickelt, produziert und vertreibt Aktivkohleprodukte auf Hartholzbasis und chemische Aktivkohle für den Einsatz in Systemen zur Kontrolle von Benzindampfemissionen in Autos, Lastwagen, Motorrädern und Booten.
Ingevity Corporation's Grundlagenzusammenfassung
| NGVT grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.55b |
| Gewinn(TTM) | -US$156.00m |
| Umsatz(TTM) | US$1.18b |
2.2x
Kurs-Umsatz-Verhältnis-16.4x
Kurs-Gewinn-Verhältnis Ist NGVT zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| NGVT Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.18b |
| Kosten der Einnahmen | US$711.70m |
| Bruttogewinn | US$466.00m |
| Sonstige Ausgaben | US$622.00m |
| Gewinn | -US$156.00m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -4.49 |
| Bruttomarge | 39.57% |
| Nettogewinnspanne | -13.25% |
| Schulden/Eigenkapital-Verhältnis | 2,842.9% |
Wie hat sich NGVT auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/20 22:09 |
| Aktienkurs zum Tagesende | 2026/06/18 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Ingevity Corporation wird von 8 Analysten beobachtet. 4 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Jonathan Tanwanteng | CJS Securities, Inc. |